1118767-15-9

Basic information

• Product Name: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester
• CAS NO: 1118767-15-9
• Molecular Weight: 943.186
• Mol File: 1118767-15-9.mol
• Article Data: 5

Chemical Properties

• Density: 1.15±0.1 g/cm3(Predicted)
• CAS DataBase Reference: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester(CAS DataBase Reference)
• NIST Chemistry Reference: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester(1118767-15-9)
• EPA Substance Registry System: 22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester(1118767-15-9)

Safety Data

• Hazardous Substances Data: 1118767-15-9(Hazardous Substances Data)

Usage

General Description

22-(tert-butoxycarbonyl)-43,43-dimethyl-10,19,24,41-tetraoxo-3,6,12,15,42-pentaoxa-9,18,23-triazatetratetracontanoic acid N-hydroxysuccinimide ester, due to its structural complexity, is likely part of the larger class of organic and bioorganic compounds known as polyethylene glycol (PEG) derivatives and protected amino acids. Its long-chain structure combined with several functional groups, including esters and carbonyl groups, suggests it may be used in the synthesis of peptides and other complex organic molecules. The N-hydroxysuccinimide ester functional group is commonly used in bioconjugation chemistry to attach molecules of interest to proteins or other substrates. The tert-butoxycarbonyl group is a protecting group used in peptide synthesis, implying this compound could feature in biochemical research and drug development. However, without specific application context or more details, it's challenging to provide a complete overview.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 843666-34-2 octadecanedioic acid tert-butyl ester-2,5-dioxopyrrolidin-1-yl ester 
• 45120-30-7 L-glutamic acid α-tert-butyl ester 
• 871-70-5 octadecanedioic acid 
• 166108-71-0 8-(9-fluorenylmethyloxycarbonyl-amino)-3,6-dioxaoctanoic acid 
• 84793-07-7 Fmoc-Glu-OtBu 
• 843666-40-0 1,18-octadecanedioic acid mono-tert-butyl ester 
• 105832-38-0 O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 

Relevant articles and documents

A METHOD FOR MODIFICATION OF PEPTIDES IMMOBILIZED ON A SOLID SUPPORT BY TRACELESS REDUCTIVELY CLEAVABLE LINKER MOLECULES

The present invention relates to a method for modifying and purifying peptides comprising an immobilizing step, a modification step and a releasing step. In the immobilizing step, a crude linker-tagged peptide L-P is coupled to a solid support yielding an immobilized linker-tagged peptide S-L-P. Subsequently, the immobilized linker-tagged peptide S-L-P is modified with one or more organic molecules yielding an immobilized linker-tagged peptide S-L-mP. Finally, the modified peptide is released via a reduced intermediate RI. The linker molecule is a compound of formula 1, X-Tbb-Vaa-U-Y-Z (1), which can be coupled to a purification resin via the moiety X and to a peptide via the moiety Y under the release of the leaving group Z. T is an optional spacer moiety and V is an optional electron withdrawing moiety. U is an aryl or 5- or 6-membered heteroaryl moiety bound to at least one electron withdrawing moiety V, W or E. The linker is stable under acidic conditions and releases the peptide upon addition of a reducing agent.

Novel GLP-1 Analogues

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

Protease stabilized acylated insulin analogues

Novel acylated insulin analoges exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analoges contain B25H and A14E or A14H.